Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 27, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 33,523 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on March 23, 2006, and was advised to the Company on March 27, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4 R (1) (b). The GSK Trust is identified as a discretionary trust where all employees or former employees are potential beneficiaries.
Investor Verification Points
- Verify the impact of the 33,523 share transfer on the total outstanding share count.
- Confirm the specific identities of the SmithKline Beecham Employee Share Option Plan 1991 participants receiving the shares.
- Review the full terms of the GSK Trust to understand the scope of employee benefits.
- Note that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the trust shares similarly to other employees.